Astellas makes a big to acquire CV Therapeutics. Japan's Astellas Pharma is offering a billion dollars in cash for CV Therapeutics. The bid comes in at $16 a share, a whopping 41 percent premium over …
Pharma News 3_29
Breaking news from the ACC: Vytorin/Zetia gets panned - shows no benefit on the primary endpoint, though effective in reducing some markers. Doctors now wary and skeptical. Merck and Schering-Plough …